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1. Introduction 
Autism spectrum disorders (ASD) and epilepsy are among the most devastating and 
common neurological disorders of childhood, with an estimated incidence of about 0.5 – 1% 
in worldwide population. Autism and epilepsy are often associated: about 30% of autistic 
patients develop epilepsy, and a relevant percentage of epileptic patients in paediatric age 
shows ASD symptoms. This suggests that – at least in certain cases – common 
neurodevelopmental bases may exist for these two diseases (Brooks-Kayal, 2010). 
The neurodevelopmental bases of both autism and epilepsy have been clearly showed by a 
number of clinical, neuroimaging and neuropathological studies. A large series of evidence 
also indicates that both autism and epilepsy have a primarily genetic origin. A wide variety 
of genes have been associated to these diseases, including genes regulating brain 
development, gene transcription, synaptic scaffolding, neurotransmission and signal 
transduction. Indeed, genetic heterogeneity is recognised as a typical feature of both autism 
and epilepsy, meaning that different mutations may result in similar disease phenotypes. 
Since autism and epilepsy are neurological disorders involving multiple genes and resulting 
in complex pathological traits, understanding the underlying mechanisms is a very difficult 
task. Moreover, even though the two diseases may have a common neurodevelopmental 
origin, a precise link between these two pathologies still remains to be determined. 
In recent years, inhibitory circuit dysfunction gained increasing attention in ASD research. 
Ǆ-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain, and 
human genetics studies clearly indicate an association between ASD and genes for GABA 
receptor subunits as well as genes controlling GABAergic neuron development or 
GABAergic synapse structure. Moreover, recent studies, performed on both animal models 
and postmortem human samples, suggest that GABAergic neurons and circuits may be 
altered in ASD. It is likely that the imbalance between excitation and inhibition resulting 
from neurodevelopmental defects in GABAergic circuitry might  represent a common cause 
for ASD and epilepsy. Here, we will review the genetic, cellular, anatomical and 
neurophysiological studies that support this hypothesis. 
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2. Genetic determinants of ASD 
ASD represent a group of very heterogeneous group of neurodevelopmental disabilities of 
proven genetic origin, with an incidence of about 60-70/10,000 (Fombonne, 2009).  A gender 
distortion is observed in ASD (4:1 males to females ratio; Abrahams & Geschwind, 2008), 
reflecting a possible involvement of the X chromosome or imprinting mechanisms. The 
genetic factors play an important role in the pathogenesis of these diseases (Persico et al., 
2006), as documented by the recurrence risk in families and twin studies. These studies 
show a concordance rate of 82–92% in monozygotic versus 1–10% in dizygotic twins. 
Heritability is estimated above 90% and sibling recurrence risk is above 6–20% (Abrahams & 
Geschwind, 2008; Toro et al., 2010). The genetic architecture of ASDs is complex; only 10–
20% of ASD patients have an identified genetic etiology, whereas in the majority of patients 
the origin of the disorder remains unknown. Genetic forms of ASD include monogenic and 
complex disorders, as well as chromosomal abnormalities. Monogenic disorders include 
neurofibromatosis (NF1), fragile X syndrome (FMR1), tuberous sclerosis (TSC1, TSC2), 
Angelman syndrome (UBEA3A) and Rett syndrome (MECP2), covering only the 2–5% of the 
ASD cases (Hatton et al., 2006). Cytogenetic investigations and genome-wide scans have 
been performed to identify chromosomal regions containing ASD susceptibility genes. 
Results from these genome-wide linkage scans indicate potential susceptibility regions that 
spread across the entire genome, but only a few loci (Freitag, 2007; Yang & Gill, 2007). The 
most common chromosomal rearrangement is the maternal duplication of 15q11-q13, which 
accounts for approximately 1-2% of ASD cases (Vorstman et al. 2006). Recent genome-wide 
association (GWA) studies have identified novel candidate loci between the cadherin genes 
CDH9 and CDH10 (5p14.1; Wang et al., 2009) and between the SEMA5A and TAS2R1 genes 
(5p15.2 ; Weiss et al., 2009). In addition, the Autism Genome Project (AGP) Consortium has 
genotyped 1,558 ASD families for one million single nucleotide polymorphisms (SNPs), 
identifying a novel locus near the gene MACROD2 (20p12.1; Anney et al., 2010). Syndromic 
forms of ASD have been associated with both copy number variations (CNVs) and rare 
mutations in several genes, including SHANK3, NLGN3, NLGN4, NRXN1 and HOXA1 
(Lintas & Persico, 2009). A recent extensive metanalysis of the literature (Betancur, 2011) 
allowed identification of 103 disease genes and 44 genomic loci reported in subjects with 
ASD or autistic behaviour. It is interesting to note that the vast majority of these genes and 
loci have been also causally implicated in epilepsy (including genes regulating brain 
development, gene transcription, synaptic scaffolding, neurotransmission and signal 
transduction), suggesting that these two neurodevelopmental disorders share common 
genetic bases (Betancur, 2011). Specifically, several evidences suggest that an impairment of 
inhibitory neurotransmission may constitute a fundamental event in the development of 
both ASD and epilepsy (Rubenstein & Merzenich, 2003). Since GABA is the major inhibitory 
neurotransmitter in the brain, here we briefly summarize the genes involved in GABAergic 
dysfunction and their relation with susceptibility to ASD and epilepsy. 
2.1 Genes regulating GABAergic neuron development 
Several genes control the process of development of GABAergic neurons, including DLX1, 
DLX2, MASH1 and RELN (Wonders & Anderson, 2006). The DLX1 and DLX2 genes encode 
homeodomain-containing transcription factors and are located head-to-head on 
chromosome 2q31, a region previously associated to autism susceptibility in several 
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genome-wide linkage studies. Two studies examining SNPs in the DLX1 and DLX2 genes 
have found an association with ASD, suggesting that common genetic variations in these 
genes play a critical role in the disease (Liu et al., 2009; Chang et al., 2010). GABAergic 
neuron development dysfunction may also occur in conjunction with abnormalities in the 
RELN gene, coding for the extracellular matrix glycoprotein Reelin which is involved in 
neuronal migration and lamination of the cerebral cortex during embryogenesis (Forster et 
al., 2002). RELN maps to 7q22 human chromosome (De Silva et al., 1997). Linkage in this 
region is among the most robust genetic findings in ASD. In family-based and case–control 
studies the 5′-untranslated region (5′-UTR) GGC repeat alleles was associated with ASD 
(Persico et al., 2001). Importantly, Reelin (the product of RELN gene) is expressed in 
GABAergic neurons the adult brain (van Kooten et al., 2005). 
Among the numerous ASD associated genes, EN2 (coding for the homeobox-containing 
transcription factor Engrailed-2) was originally shown to be involved in posterior brain 
(mesencephalon/hidbrain) embryonic development (Joyner et al., 1991). Recent studies on 
En2 null mice suggest that En2 deletion may alter GABAergic circuitry in the adult brain 
(Tripathi et al., 2009; see section 3.3.2). EN2 maps to a region of chromosome 7 implicated in 
ASD susceptibility, and GWA studies indicated EN2 as a candidate gene for ASD (Benayed 
et al., 2009). Namely, two SNPs in the human EN2 gene have been associated to ASD, one of 
which (rs1861973, A-C haplotype) is functional: when tested in a luciferase reporter assay in 
rat, mouse and human cell lines, this SNP markedly affected EN2 promoter activity 
(Benayed et al., 2009). 
2.2 Genes coding for GABAA receptor subunits 
Genes coding for GABA receptors has been extensively studied to evaluate their role in the 
pathogenesis of ASD. Three classes of GABA receptors exist in the mature mammalian 
brain, named as GABAA, GABAB and GABAA-rho (GABAC). GABAA receptor is a ionotropic 
receptor that allows chloride ion fluxes through the neuronal membrane. Nearly 20 GABAA 
subunits have been reported in humans (Olsen & Sieghart, 2009). Mutations in GABAA 
receptor subunits genes have been associated to ASD. The chromosome 15q11, containing 
the genes coding the three GABAA receptor subunits ǂ5, ǃ3 and Ǆ3 (GABRA5, GABRB3 and 
GABRG3, respectively) has been linked to ASD, and SNPs in the above mentioned genes 
have been associated to ASD (Buxbaum et al., 2002; Hogart et al., 2007, 2009). It is interesting 
to note that, among these genes, GABRB3 has also been indicated as susceptibility gene for 
childhood absence epilepsy (Urak et al., 2006).  
2.3 Genes involved in GABAergic synapse structure and function 
Different genes involved in the development and function of inhibitory GABAergic 
synapses have been associated to ASD. Neurexins (NRXNs) are presynaptic proteins, 
binding postsynaptic neuroligins. This interaction is thought to trigger postsynaptic 
differentiation and control the balance of inhibitory GABAergic and excitatory 
glutamatergic inputs (Graf et al., 2004; Scheiffele et al., 2000). There are three NRXN genes 
(NRXN 1–3) in mammals; among these, mutations and chromosomal rearrangements in 
NRXN1 has been associated with ASD (Feng  et  al., 2006; Kim et al., 2008; Wisniowiecka-
Kowalnik et al., 2010). Recently it has been shown that NRXNs can bind not only 
Neuroligins (NLGNs) but also GABAA receptors (Zhang et al., 2010). The effect of this 
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ligand-receptor interaction decreases GABAergic transmission. NLGNs are neural cell 
adhesion molecules, which act as ligands for neurexins (Graf et al., 2004; Scheiffele et al., 
2000). NLGNs play a key role in the formation, organization, and remodeling of synapses 
and different isoforms are associated with different synaptic types. NLGN1, NLGN4X and 
NLGN4Y are localized at glutamatergic synapses (Persico et al., 2006; Craig & Kang, 2007). 
NLGN3 is present in both excitatory and inhibitory synapses (Chih et al., 2005; Budreck & 
Scheiffele, 2007), whereas NLGN2 is located in GABAergic synapses (Craig & Kang, 2007; 
Persico et al., 2006; Varoqueaux et al., 2006). Mutations in NLGN1, 3 and 4X genes have been 
identified in patients with familial ASD (Jamain et al., 2003; Laumonnier et al., 2004; 
Lawson-Yuen et al., 2008). 
The MECP2 gene, coding for the epigenetic regulator methyl-CpG-binding protein 2, is the 
causative gene for Rett syndrome, which belong to the family of ASD. Rett syndrome is 
characterized by loss of language capability, motor stereotyped behaviors, severe mental 
retardation and seizures (Chahrour & Zoghby, 2007). Recent studies indicate that Mecp2 
dysfunction in GABAergic interneurons severely impacts GABA signaling and results in 
ASD-like phenotypes in the mouse (Chao et al., 2010; see section 3.3.6). 
Fragile X syndrome (FXS) is one of the disorders included in ASD. FXS is caused by an 
expansion of the trinucleotide repeat in the promoter region of the fragile X mental 
retardation 1 (FMR1) gene (Verkerk et al., 1991).  FMR1 gene encodes the fragile X mental 
retardation protein (FMRP), a mRNA binding protein with a key role in the intracellular 
transport and translation of 4–8% of synaptic proteins (Bassell & Warren, 2008). Recent 
evidence also indicates the involvement of the GABAergic system in the pathogenesis of 
FXS (D’Hulst & Kooy, 2007, 2009; Olmos-Serrano et al., 2010; see also 3.3.7).  
3. Deficits of GABAergic neurons and circuits in ASD 
From the literature data reported in the previous chapter, it is evident that genetic defects in 
genes regulating GABAergic neuron development as well as GABAergic synapse structure 
and function are crucially involved in ASD pathogenesis. Alterations of GABAergic neurons 
and circuits have been reported in postmortem brain tissue samples from ASD patients, as 
well as in mouse models of the disease. Here we will review the more significant findings 
from these studies. 
3.1 GABAergic neuron defects in the brain of ASD patients 
The analysis of postmortem tissues revealed that many brain regions are affected in ASD 
patients, including the cerebral cortex, limbic system and cerebellum. Minicolumns 
represent the cellular and functional organization of glutamatergic and GABAergic neurons 
in the cerebral cortex (De Felipe et al., 1990; Mountcastle, 1997; Polleux & Lauder, 2004). 
Minicolumns are anatomically characterized by vertical arrays of pyramidal neurons with 
their dentrides and axon projections. Pyramidal cells arrays are accompanied by their 
GABAergic interneurons that establish synapses with pyramidal cells bodies, their axons 
emergences and dentrites. A narrowing of cortical minicolumns (namely, a reduced distance 
between columns) has been shown in ASD patients (Casanova et al., 2002). This reduced 
intercolumnar distance was proposed to depend on structural/anatomical defects in 
GABAergic interneurons surrounding principal pyramidal cortical neurons (Casanova 2003; 
Casanova & Trippe 2009, Raghanti et al., 2010). An increased cell density and a reduced cell 
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size have long been reported in the limbic system of ASD patients (Kemper & Bauman, 
1993). More recently, a significant increase in the number of parvalbumin-, calbindin- and 
calretinin-positive interneurons has been reported in the hippocampus of ASD patients 
(Lawrence et al., 2010). In the cerebellum, a clear reduction in the number of inhibitory 
Purkinje neurons has long been reported in ASD postmortem tissues (Kemper & Bauman, 
1993). More recent studies confirmed the selective loss of calbindin-positive Purkinje cells 
but not parvalbumin-positive stellate and basket interneurons in the ASD cerebellum 
(Whitney et al., 2008, 2009).  
3.2 GABAergic signaling deficits in the brain of ASD patients 
Several studies suggest a GABAergic signaling dysfunction in ASD, mainly due to altered 
levels of the GABA synthetic enzyme (glutamic acid decarboxylase, GAD) and GABA 
receptors. Two GAD isoforms exist, named GAD65 (GAD2) and GAD67 (GAD1), 
respectively localized on chromosome 10 and 2 in humans (Karlsen et al., 1991; Kaufman et 
al., 1991; Martin & Rimvall, 1993). Several studies were conducted in post-mortem brains of 
autistic patients focusing on parietal cortices and cerebellar alterations in terms of GAD 
proteins amount and Purkinje cells quantification. A 50% reduction in GAD65/67 proteins 
levels was reported in the cerebellum and parietal cortex from ASD patients (Fatemi et al., 
2002). Accordingly, reduced levels of GAD67 and GAD65 mRNAs were also detected in 
Purkinje cells and dentate nuclei neurons in the cerebellum from ASD cases (Yip et al., 2007, 
2008). Interestingly, the same author also reported an increase of GAD67 mRNA levels in 
GABAergic basket cells in the cerebellar molecular layer that was interpreted as a 
compensatory up-regulation to supply the loss of Purkinje cells in ASD brains (Yip et al., 
2008). Several studies showed a significant decrease in GABAA receptor ǂ4, ǂ5, ǃ1 and ǃ3 
subunits (Blatt et al. 2001; Fatemi et al., 2010, Samaco et al. 2005), as well as a significat 
reduction of benzodiazepine (the GABAA receptor ligand) binding sites (Oblak et al., 2011) 
in ASD brains. GABAB receptors were also reduced in restricted regions of the cerebral 
cortex from ASD patients (Oblak et al., 2010). Importantly, a recent preliminary study 
performed by transcranial magnetic stimulation allowed to detect a reduced cortical 
inhibition (interpreted as a possible disruption of GABAA receptor activity) in the brain of a 
subset of ASD patients (Enticott et al., 2010). Taken together, these data support the 
hypothesis of a GABAergic signaling deficit in ASD. 
3.3 Evidence from animal studies 
Impaired function of inhibitory circuits has been proposed as a major pathogenic cause of 
ASD (Rubenstein & Merzenich, 2003). Evidence is essentially limited to human genetic 
association studies as well as expression analyses performed on postmortem samples from 
ASD and control patients (see above). Conversely, this hypothesis is strongly supported by a 
vast number of studies performed on animal models recapitulating different aspects of the 
ASD pathology. So far, several transgenic and pharmacological mouse models have been 
developed to mimic different features of ASD-like syndromes. These include mutant mice 
for DLX1/2, EN2, GABRB3, RELN, NLGN3, MECP2 and FMR1. 
Different anatomical and functional deficits of the GABAergic system were discovered in all 
these mouse models, and loss of parvalbumin (PV) expressing interneurons seems to be a 
hallmark of ASD-like dysfunctions in all models analyzed. The physiological formation of 
synaptic connections between PV-positive interneurons and principal pyramidal neurons 
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has been implicated in functional maturation of the postnatal cerebral cortex, and deficits 
in this process have been proposed as a pathogenic mechanism of ASD (Di Cristo, 2007). 
PV-positive interneurons approximately represent the 40% of GABAergic interneurons of 
the cerebral cortex, and comprise basket and chandelier fast spiking cells (Rudy et al., 
2010). The other two principal groups of cortical interneurons are somatostatin (SST) 
positive neurons (about 30%) and neurons expressing the 5HT3a serotonin receptor 
(about 30%); other less-represented cortical interneuron subtypes are those expressing the 
calcium binding proteins calretinin (CR) and calbindin (CB) and neuropeptide Y (NPY) 
(Rudy et al., 2010). Defects in different interneuron subtypes, and more generally in the 
anatomical organization and physiological function of the GABAergic system, have been 
reported in several mouse models of ASD. The principal findings are described in the 
following paragraphs. 
3.3.1 Dlx1/2 knockout mice 
The family of Dlx homeobox transcription factors regulates the development of inhibitory 
interneurons; members of this family, namely Dlx1, Dlx2, Dlx5, and Dlx6, control the 
differentiation of GABAergic neurons in basal ganglia and cerebral cortex (Pleasure, 2000). 
The principal finding reported in Dlx1/2 mutant mice is a migration defect of GABAergic 
interneurons into the cerebral cortex (Anderson et al., 1997a, 1997b). Dlx1 null mice 
displayed a selective loss of SST-, NPY-, CR- and reelin-expressing interneurons 
accompanied by reduced GABAergic inhibitory transmission and late-onset epilepsy (Cobos 
et al., 2005). More recently, additional behavioural abnormalities (such as conditioned fear 
response) linked to impairment of GABAergic systems were described in Dlx1-null mice 
(Mao et al., 2009). 
3.3.2 Engrailed2 knockout mice 
En2 null mice have been proposed as a model for ASD, due to their complex anatomical and 
behavioural phenotype. En2 null mice display cerebellar hypoplasia and a reduced number 
of Purkinje cells (Joyner et al., 1991; Kuemerle et al., 1997). These abnormalities resemble 
some of those reported in ASD (see section 3.1). Importantly, ASD-like behaviours such as 
decreased play, reduced sociality and impaired spatial learning and memory were described 
in these mutants (Cheh et al., 2006). Recently we showed an increased susceptibility to 
seizures in En2 null mice, that was accompanied by reduced PV immunostaining on cell 
bodies of CA3 pyramidal neurons, and reduced SST immunostaining in the the stratum 
lacunosum moleculare of the hippocampal formation (Tripathi et al., 2009). These findings 
suggest that the En2 gene may be involved in GABAergic system development and 
maintenance, and altered En2 function may be a common cause of ASD and seizures. 
3.3.3 GABRB3 knockout mice 
Mice lacking the GABAA receptor subunit ǃ3 (GABRB3) display high mortality rate and 
symptoms consistent to Angelman’s syndrome, including learning and memory deficits, 
poor motor skills, stereotyped behaviours and seizures suscetibility (Homanics et al., 1997; 
DeLorey et al., 1998). More recently, GABRB3 gene deficient mice have been shown to 
exhibit impaired social and exploratory behaviors, deficits in non-selective attention and 
hypoplasia of cerebellar vermal lobules, thus resempling a wide renge of ASD phenotypes 
(DeLorey et al., 2008). 
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3.3.4 Reeler mice 
Reelin is an extracellular glycoprotein belonging to the family of serine proteases (Fatemi et 
al., 2005). Reelin binding to membrane receptors enhances signal transduction pathways 
leading to synaptic plasticity and axonal growth (Beffert, 2005). Reeler mice are lacking the 
Reelin gene. In these mice, neuronal migration in the cerebral cortex is dramatically 
impaired. This results a disorganization of laminated brain regions as cerebral cortices and 
cerebellum (Curran & D’Arcangelo, 1998). Reeler also mice show a decrease of dentritic 
spine density and a decreased GABA metabolism turnover (Carboni, 2004). ASD-like 
behaviours and loss of PV interneurons was recently reported in Reeler mice (Macrì et al., 
2010). 
3.3.5 NLGN3 knock-in mice 
Mice carrying the R451C mutation in the NLGN3 gene show behavioural phenotypes 
related to ASD (lack of social behaviours, reduced ultrasound vocalization; Radyushkin et 
al., 2009; Tabuchi et al., 2007). In addition, Nlgn3 R451C knock-in mice present an increase in 
the number of GABAergic synapses (as evaluated by vesicular GABA transporter and 
gephyrin immunostaining) and in the amplitude of inhibitory currents, suggesting that the 
R451C mutation switches Nlgn3 synaptic specificity from glutamatergic to GABAergic 
(Tabuchi et al., 2007). Further characterization of these mutants demonstrated that loss of 
parvalbumin-positive basket cells is detectable across the two hemispheres in these mice 
(Gogolla et al., 2009).  
3.3.6 Mecp2 knockout mice 
Several conditional MeCp2 mutants mice were generated in order to remove Mecp2 from 
distinct neuronal populations. With respect to ASD, the most interesting data were recently 
obtained in conditional mutants lacking Mecp2 in inhibitory neurons expressing Viiat 
(Vesicular inhibitory aminoacid transporter, required to load GABA and glycine into 
synaptic vesicles) (Chao et al., 2010). Viaat-Mecp2 conditional mutants started to exhibit 
ASD-like repetitive and stereotyped behaviours, developing also self-injury behaviours. 
Interneurons immunolabelling in Viaat-Mecp2 mutants also showed a reduction of GAD65 
and GAD67 mRNA in the cerebral cortex. Mecp2 loss in inhibitory neurons also resulted in 
EEG abnormalities and seizures. Moreover, electrophysiological recordings showed 
decreased miniature inhibitory post-synaptic currents (mIPSC) in cortical slices of Viaat-
Mecp2 mutants, demonstrating that Mecp2 deficiency in GABAergic neurons determines a 
reduction of GABA neurotransmitter release due to a reduction of GAD amount in 
presynaptic terminals. Thus, loss of Mecp2 in inhibitory neurons might be a crucial 
determinant of severe forms of ASD. 
3.3.7 Fmr1 knockout mice 
Several studies show a strong reduction in the expression of GABAA receptor subunit 
mRNAs and proteins in adult Fmr1 knockout mice (Adusei et al., 2010; D’Hulst et al., 2009), 
that is accompanied by abnormal GABAergic transmission (Centonze et al., 2008; Curia et 
al., 2009), deficits of PV (but not CB- or CR-) cortical interneurons (Selby et al., 2007) and 
increased audiogenic seizure susceptibility (Musumeci et al., 2007). Table 1 summarizes the 
major GABAergic deficits described in ASD mouse models. 
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Mouse  Genetics Signaling Anatomy Behaviour Seizures 
Sections in 
text 
Dlx1/2 
null 
SNPs in 
Dlx1/2 
genes found 
in  
ASD 
patients 
- 
Interneuron 
migration 
defects 
Loss of SST, 
NPY, CR and 
reeling 
interneurons 
Impaired 
conditioned 
fear response 
Late-onset 
epilepsy 
2.1 
3.3.1 
En2 
null 
SNP found 
in  
ASD 
patients 
- 
Cerebellar 
hypoplasia 
Reduced PV and 
SST staining in 
hippocampus 
Learning and 
memory 
deficit 
Reduced 
social 
behaviours 
Increased 
susceptibility 
to kainic acid 
2.1 
3.3.2 
Gabrb3 
null 
Mutation in 
Gabrb3  
linked  to 
ASD 
- 
Cerebellar 
hypoplasia 
Learning and 
memory 
deficit 
Stereotypies 
Attention 
deficits 
Yes 
2.2 
3.3.3 
4.2.1 
Reeler 
GGC repeat 
in 5’UTR 
associated 
with ASD  
Decreased 
GABA 
metabolism 
turnover 
Neuronal 
migration 
defects 
Abnormal 
lamination of 
cerebral cortex 
and cerebellum 
Loss of PV 
interneurons 
ASD-like 
behaviours 
Yes 
2.1 
3.3.4 
Nlgn3 
R451C 
knock-in 
R451C 
mutation is 
causative of 
ASD 
Increased 
IPSCs 
Increased 
mumber of 
GABAergic 
synapses 
Loss of PV 
interneurons 
Lack of social 
behaviours 
Reduced 
ultrasound 
vocalization 
- 
2.3 
3.3.5 
Mecp2 
knockout 
in GABA 
neurons 
Mecp2 
mutation is 
causative of 
Rett 
syndrome 
Decreased 
GAD 
mRNA 
Decreased 
IPSCs 
Loss of GABA 
interneurons 
(cerebral cortex)
ASD-like 
behaviours 
Yes 
2.3 
3.3.6 
Fmr1 
null 
Fmr1 
mutation is 
causative of 
Fragile X 
syndrome 
Reduced 
GABAA 
receptor 
subunit 
mRNAs  
and GABA 
transmission
Loss of PV 
interneurons 
(cerebral cortex)
- 
Audiogenic 
seizures 
2.3 
3.3.7 
Table 1. GABAergic defects in genetic mouse models of ASD. 
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4. GABAergic dysfunction in autism and epilepsy 
Epilepsy is a neurological disorder characterised by spontaneous recurrent seizures. 
Epilepsy, similar to ASD, is increasingly being considered as a spectrum disorder due to the 
range of pathologies, seizures and behavioural and cognitive deficits associated with it 
(Jensen, 2011). As with ASD, epileptic seizures are considered to be as a result of imbalance 
between excitation and inhibition in the brain (Bradford, 1995; Olsen & Avoli, 1997). It is of 
particular relevance to developmental disorders, since seizures are the most common 
neurological emergency in children and occur most frequently in the first two years of life 
(Hauser, 1990; Chin et al., 2006), a critical period in brain development. 
A strong association has been shown between epilepsy and ASD. The incidence of epilepsy 
in ASD has been reported to be between 5 – 40% (Canitano, 2007).  Factors such as referral 
criteria, age and severity of cognitive impairments all contribute to the variability in report 
rate (Canitano, 2007; Tuchman et al., 2009). Children that co-express autism and epilepsy 
show a poorer outcome in cognitive and adaptive behaviour than those without epilepsy 
(Danielsson et al., 2005; Hara, 2007). The severity of the epilepsy phenotype seems to be 
closely related to the severity of ASD and is not associated with one particular type of 
seizure; simple and complex partial seizures, atypical absence, tonic-clonic and myoclonic 
seizures have all been reported. In particular, coexpression of mental retardation with 
autism is a risk factor for epilepsy (Volkmar & Nelson, 1990). Early onset of seizure is also 
an indicator of poor outcome in children with ASDs with more developmental disorders 
and greater seizure intractability reported (Wong, 1993; Bombardieri et al., 2010). “Seizures 
beget seizures” was a phrase coined by Sir William Gowers in 1881 and it may go some way 
to explaining this poorer outcome associated with early onset of ASD and seizures. Where 
seizures are initially a manifestation of the underlying imbalance in excitation/inhibition 
they may ultimately contribute to progressive increase in seizure severity and secondarily, 
behavioural and cognitive deficits. This is particularly evident in the developing brain 
where susceptibility to seizure-induced neuropathology leads to epilepsy and further 
cognitive deficits in later life (Ben-Ari, 2006; Ben-Ari & Holmes, 2006). Here we examine the 
link between ASD and epilepsy with particular focus on the role of GABAergic dysfunction 
of the pathogenesis of these diseases. In particular, we will describe some of the key human 
and animal studies further outlining the link between epilepsy and ASD (e.g., the presence 
of mental retardation) and the potential mechanistic role of GABA dysfunction. 
4.1 Clinical evidence of a role for GABAergic involvement in epilepsy-autism 
disorders 
An increasing number of studies have implicated the GABAergic system dysfunction in 
epilepsy and ASD. Chromosome 15q, which contains genes coding for GABA receptor 
subunits, has been reported to be a common site for mutations in ASDs (Schroer et al., 1998). 
This data is further supported by association studies linking GABA receptor subunit genes 
and SNPs associated with autism and seizures (Collins et al., 2006). An increasing body of 
evidence suggests a downregulation of GABAergic function is critical in ASD-associated 
epilepsy. Quantitative receptor autoradiographic studies examining the density and 
distribution of GABAergic subunits indicated a downregulation of GABAergic function in 
the hippocampus of ASD patients with seizures (Blatt et al., 2001). Furthermore, altered 
packing of GABAergic interneurons in the CA1 and CA3 hippocampal subfields where 
malformations are associated with the generation of seizures (Bauman & Kemper, 2005). 
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Supporting this human studies have demonstrated that there is a loss of inhibitory 
interneurons in the epileptic brain (Zhu et al., 1997; Wittner et al., 2001).  
As outlined above, FXS is one such autism-related disorder that is a leading cause of mental 
retardation (Bardoni et al., 2006). It is also strongly associated with abnormal EEG activity 
with a mean epilepsy prevalence of between 22 – 25% (Wisniewski et al., 1991; El Idrissi et 
al., 2005). Fragile X appears to have a wide profile with some reporting a benign condition 
with generalised seizures responding well to antiepileptic drugs (AEDs) treatment 
(Wisniewski et al., 1991) that disappear after childhood. Other groups report long lasting 
generalised and partial epilepsy and EEG abnormalities in adults with fragile X 
(Sabaratnam, 2000). Furthermore, Gauthey et al describe a more severe phenotype with 
children with fragile X presenting with status epilepticus (seizures lasting > 30 min) at their 
initial seizure with recurrent prolonged seizures on follow-up (Gauthey et al., 2010). Status 
epilepticus in the developing brain is known to significantly increase the risk of epilepsy, 
hippocampal sclerosis and further behavioural and cognitive deficits in later life in human 
and animals studies (Raspall-Chaure et al., 2006; Dunleavy et al., 2010). There is a large 
amount of data from animal studies (described above) to support a role for disruption of 
normal GABAergic function in seizure generation in FXS. 
Rett syndrome is a postnatal neurodevelopmental disorder typically emerging between 6 – 
18 months of age consisting of progressive loss of cognitive and motor function and the 
emergence of epilepsy (Chahrour and Zoghbi, 2007). Seizures have been reported to be 
present in between 50 – 90% of patients (Witt Engerstrom, 1992; Steffenburg et al., 2001). As 
with FXS, epilepsy is most severe through childhood and young adulthood while the 
phenotype ranges from mild seizures that are well controlled with AEDs to refractory 
epilepsy, most common types being partial complex and tonic-clonic seizures (Steffenburg 
et al., 2001; Jian et al., 2006). 
4.2 Experimental evidence of a role for GABAergic involvement in epilepsy-autism 
disorders 
There are two main aspects to the role of GABA dysfunction in the pathogenesis of epilepsy 
in autism. Firstly, absence of GABA signaling results in loss of inhibitory neuronal firing 
that normally prevents the spread of paroxysmal discharge. Furthermore, normal 
GABAergic function is integral in the brain development alteration in this function can have 
significant effects on neuronal migration, differentiation, synaptogenesis and circuit 
formation. Presently, we will outline the current data from animal studies and examine the 
mechanisms involved in these processes. 
4.2.1 Reduced GABA transmission 
GABAergic inhibition can be affected in two ways, presynaptically by a reduction in GABA 
release into the synapse or postsynaptically by an alteration in GABA receptor function. 
There is some evidence that both of these situations may contribute in epilepsy-autism 
disorders. GAD65 is one of two glutamate decarboxylase isoforms that synthesis GABA in 
the brain. Previously linked to animal models of ASD, GAD65 knockout mice have also been 
shown to display an epileptic phenotype, with animals undergoing spontaneous seizures 
involving the limbic system (Kash et al., 1997). The presence of the seizures and altered 
behaviour was attributed to the loss of tonic inhibition to prevent hyperexcitability in the 
developing nervous system (Stork et al., 2000). GABAA receptor dysfunction has been well 
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documented the hippocampus and neocortex in human epilepsy (Loup et al., 2000, 2006). 
Animal models of temporal lobe epilepsy (Pirker et al., 2003) and absence seizures (Li et al., 
2006) suggest alterations in receptor subunit expression and receptor localization as 
potential mechanisms. Data is limited for epilepsy-autism disorders, however mice lacking 
the GABAA receptor subunit ǃ3 (see above) displays altered EEG along with a reduced 
threshold to chemoconvulsant seizures (DeLorey et al., 1998; Liljelund et al., 2005). 
4.2.2 Altered brain development as a result of GABAergic dysfunction 
In addition to the direct effect of altered GABA system on the ability of interneurons to 
inhibit the generation of synchronized discharges, there are a vast array of ASD candidate 
genes involved in secondary regulation of the GABAergic system during development that 
may play a role in the pathogenesis of epilepsy-autism disorders.  
The effects of Mecp2 and En2 mutations on interneuron and seizure susceptibility has been 
described in the previous sections. Similarly, deficits in inhibitory interneurons and reduced 
seizure threshold were observed in neuropilin 2 (NPN2) deficient mice (Gant et al., 2009). 
The gene for NPN2 (also known as NRP2) is coded for at 2q34, a region known to be 
strongly associated with autism (Wu et al., 2007). NPN2 functions as a chemorepulsive 
receptor for the axon guidance molecule Semaphorin 3F, and together regulate neuronal 
migration and differentiation, contributing to brain development and network formation. 
NPN2 deficient mice had shorter seizure latencies, increased vulnerability to seizure-
induced neuronal death and developed chemically-induced spontaneous recurrent seizures 
(Gant et al., 2009). Importantly, NPN2 null mice had a reduced number of GABA, PV and 
NPY interneurons (Gant et al., 2009).  
As described in the table above, Fmr1 mutant mice also showed increased susceptibility to 
audiogenic seizures (Musumeci et al., 2000) but not chemoconvulsants (Chen & Toth, 2001). 
An imbalance in the inhibition–excitation system (mainly due to reduced GABAA receptor 
expression;  El Idrissi et al., 2005) is thought to be the major cause of increased susceptibility 
to seizures in these mutants. Importantly, hyperexcitibility of Fmr1 mutant mice was shown 
to be reduced by pharmacological intervention with a GABAergic agonist, augmenting tonic 
inhibitory tone (Olmos-Serrano et al., 2010). 
Taken together, all these data provide a sound rationale for proposing GABA dysfunction, 
primarily through loss of GABA transmission, and secondarily, through altered circuit 
formation in development, as a potential link between epilepsy and autism, possibly even a 
common pathology. The range of genes involved may reflect the spectrum of pathologies 
associated with autism and epilepsy and warrant more detailed investigation. Overall, these 
data indicate that the ASD-epilepsy condition is a spectrum disorder within itself. It appears 
that the severity of the autism condition, presence or absence of mental retardation, is 
closely associated with the epilepsy phenotype, in seizure frequency, severity and 
intractability. Early diagnosis and suitable treatment protocols are vital for successful 
outcomes (Tuchman, 2000; Bombardieri et al., 2010). The Australian Rett Syndrome 
Database (Laurvick et al., 2006) is an ongoing longitudinal study profiling the progression of 
the disease in a growing cohort of cases. Similar properly constructed prospective clinical 
studies throughout ASD could provide vital insights required to develop successful 
therapeutic approaches for epilepsy in ASD. Key to advancing the experimental models will 
be temporal and spatial conditional deletions of various levels of the signaling system will 
allow greater insight into the contributions of the various genes in migration, differentiation 
and circuit formation. 
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4.3 Antiepileptic drugs in epilepsy-autism disorders 
Due to the clinical heterogeneity of epilepsy and ASD significant issues exist regarding the 
treatment of epilepsy in children with ASD. Current treatment of epilepsy in ASD patients is 
based on the existing strategies for treating childhood epilepsy. Treatment with traditional 
AEDs such as phenobarbital, valproic acid and lamotrigine have all been shown to reduce 
abnormal EEG discharge (Depositario-Cabacar & Zelleke, 2010). Although, despite some 
studies reporting improved cognitive performance following treatment, the results from 
other studies are equivocal. It is clear, however, that there is an increased risk of the patient 
being refractory to treatment where developmental disabilities coexist (Alvarez et al., 1998; 
Airaksinen et al., 2000). 
Studies of treatment on non autism-related epilepsies in children also raise a number of 
concerns about effects of AED treatment which are relevant to the current discussion. GABA 
is the principal inhibitory neurotransmitter in the adult brain. However, during embryonic 
development and up until early postnatal development in both humans and rodents, high 
expression of the Na+/K+/2Cl- (NKCC1) cotransporter and weak expression of the K+/Cl- 
cotransporter (KCC2) are present. As a result, opening of the GABAergic channels leads to 
depolarization and excitation of the neuron (Ben-Ari, 2002). There is an increasing body of 
evidence that this property of GABAergic neurons in the developing brain plays a crucial 
role in the development of normal neuronal circuitry, facilitating the development of both 
inhibitory and excitatory synapses (Akerman & Cline, 2007). In this respect, the use of 
GABAergic agonists to treat seizures in ASD children during developmental age might 
increase excitation and could result detrimental. In addition, approximately 30% of children 
are refractory to AED treatment (Treiman et al., 1998; Lowenstein, 2006). Furthermore, when 
epileptic seizures are successfully suppressed, AED treatment is associated with decreased 
cognitive and behavioural developmental outcomes (Loring et al., 2007), which may play a 
role in exacerbating the autistic condition, or at least moderate the positive outcome from 
absence of seizures (Tuchman, 2000). Careful monitoring for behavioural and cognitive side-
effects is required since they still have the potential to exacerbate the existing ASD-related 
deficits. Elucidating the role of GABA dysfunction in autism-epilepsy disorders will provide 
greater insight into the pathogenesis of these diseases and hopefully facilitate more targeted 
approach producing improved outcomes in both disorders. 
5. Conclusion 
ASD and epilepsy both have a clear neurodevelopmental origin, and are characterized by a 
high degree of genetic heterogeneity. Genes regulating brain development, gene 
transcription, synaptic scaffolding, neurotransmission and signal transduction have been 
implicated in their pathogenesis, indicating that these two neurodevelopmental disorders 
may share common genetic bases. Indeed, epilepsy and ASD are often associated. Typically, 
severe forms of ASD and ASD-related pathologies always present seizures. Defects in the 
development, maintenance and function of GABAergic interneurons in the cerebral cortex 
and other brain areas have been postulated as a pathogenic mechanism of ASD-epilepsy 
syndromes. However, a direct, causal demonstration of a defect of GABAergic 
neurotransmission in restricted brain areas of ASD patients is still lacking. Conversely, 
evidence from several genetic mouse models of ASD strongly supports the hypothesis of 
GABAergic dysfunction in ASD-epilepsy. In the near future, it will be crucial to use these 
models to test the efficacy of GABAergic drugs to rescue ASD-like anatomical, physiological 
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and behavioural deficits in preclinical studies. If successful, these studies might contribute 
to developing novel therapies against human ASD. 
6. Acknowledgment 
S.G., G.P. and M.D. equally contributed to this study. M.D. and P.S. are postodctoral fellows, 
respectively supported by IRCSET (Ireland) and Provincia Autonoma di Trento (Italy) 
under the Marie Curie-People cofunding action of the European Community. This work was 
funded by the Italian Ministry of University and Research (PRIN 2008 grant # 
200894SYW2_002) and the University of Trento (CIBIO start-up grant).  Correspondence 
should be addressed to Yuri Bozzi, Laboratory of Molecular Neuropathology, Centre for 
Integrative Biology (CIBIO), University of Trento, Italy (bozzi@science.unitn.it). 
7. References 
Abrahams, B. S. & Geschwind, D. H. (2008). Advances in Autism Genetics: On the Threshold 
of a New Neurobiology. Nat Rev Genet, Vol.9, No.5, May, pp.341-355,1471-0064     
Adusei, D. C., Pacey, L. K., Chen, D. & Hampson, D. R. (2010). Early Developmental 
Alterations in Gabaergic Protein Expression in Fragile X Knockout Mice. 
Neuropharmacology, Vol.59, No.3, Sep, pp.167-171,1873-7064       
Airaksinen, E. M., Matilainen, R., Mononen, T., Mustonen, K., Partanen, J., Jokela, V. & 
Halonen, P. (2000). A Population-Based Study on Epilepsy in Mentally Retarded 
Children. Epilepsia, Vol.41, No.9, Sep, pp.1214-1220,0013-9580     
Akerman, C. J. & Cline, H. T. (2007). Refining the Roles of Gabaergic Signaling During 
Neural Circuit Formation. Trends Neurosci, Vol.30, No.8, Aug, pp.382-389,0166-2236     
Alvarez, N., Besag, F. & Iivanainen, M. (1998). Use of Antiepileptic Drugs in the Treatment 
of Epilepsy in People with Intellectual Disability. J Intellect Disabil Res, Vol.42 Suppl 
1, Dec, pp.1-15,0964-2633     
Anderson, S. A., Eisenstat, D. D., Shi, L. & Rubenstein, J. L. (1997a). Interneuron Migration 
from Basal Forebrain to Neocortex: Dependence on Dlx Genes. Science, Vol.278, 
No.5337, Oct 17, pp.474-476,0036-8075     
Anderson, S. A., Qiu, M., Bulfone, A., Eisenstat, D. D., Meneses, J., Pedersen, R. & 
Rubenstein, J. L. (1997b). Mutations of the Homeobox Genes Dlx-1 and Dlx-2 
Disrupt the Striatal Subventricular Zone and Differentiation of Late Born Striatal 
Neurons. Neuron, Vol.19, No.1, Jul, pp.27-37,0896-6273     
Anney, R.,Klei, L.,Pinto, D.,Regan, R.,Conroy, J.,Magalhaes, T. R.,Correia, C.,Abrahams, B. 
S.,Sykes, N.,Pagnamenta, A. T.,Almeida, J.,Bacchelli, E.,Bailey, A. J.,Baird, 
G.,Battaglia, A.,Berney, T.,Bolshakova, N.,Bolte, S.,Bolton, P. F.,Bourgeron, 
T.,Brennan, S.,Brian, J.,Carson, A. R.,Casallo, G.,Casey, J.,Chu, S. H.,Cochrane, 
L.,Corsello, C.,Crawford, E. L.,Crossett, A.,Dawson, G.,de Jonge, M.,Delorme, 
R.,Drmic, I.,Duketis, E.,Duque, F.,Estes, A.,Farrar, P.,Fernandez, B. A.,Folstein, S. 
E.,Fombonne, E.,Freitag, C. M.,Gilbert, J.,Gillberg, C.,Glessner, J. T.,Goldberg, 
J.,Green, J.,Guter, S. J.,Hakonarson, H.,Heron, E. A.,Hill, M.,Holt, R.,Howe, J. 
L.,Hughes, G.,Hus, V.,Igliozzi, R.,Kim, C.,Klauck, S. M.,Kolevzon, A.,Korvatska, 
O.,Kustanovich, V.,Lajonchere, C. M.,Lamb, J. A.,Laskawiec, M.,Leboyer, M.,Le 
Couteur, A.,Leventhal, B. L.,Lionel, A. C.,Liu, X. Q.,Lord, C.,Lotspeich, L.,Lund, S. 
C.,Maestrini, E.,Mahoney, W.,Mantoulan, C.,Marshall, C. R.,McConachie, 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
38
H.,McDougle, C. J.,McGrath, J.,McMahon, W. M.,Melhem, N. M.,Merikangas, 
A.,Migita, O.,Minshew, N. J.,Mirza, G. K.,Munson, J.,Nelson, S. F.,Noakes, C.,Noor, 
A.,Nygren, G.,Oliveira, G.,Papanikolaou, K.,Parr, J. R.,Parrini, B.,Paton, T.,Pickles, 
A.,Piven, J.,Posey, D. J.,Poustka, A.,Poustka, F.,Prasad, A.,Ragoussis, J.,Renshaw, 
K.,Rickaby, J.,Roberts, W.,Roeder, K.,Roge, B.,Rutter, M. L.,Bierut, L. J.,Rice, J. 
P.,Salt, J.,Sansom, K.,Sato, D.,Segurado, R.,Senman, L.,Shah, N.,Sheffield, V. 
C.,Soorya, L.,Sousa, I.,Stoppioni, V.,Strawbridge, C.,Tancredi, R.,Tansey, 
K.,Thiruvahindrapduram, B.,Thompson, A. P.,Thomson, S.,Tryfon, A.,Tsiantis, 
J.,Van Engeland, H.,Vincent, J. B.,Volkmar, F.,Wallace, S.,Wang, K.,Wang, 
Z.,Wassink, T. H.,Wing, K.,Wittemeyer, K.,Wood, S.,Yaspan, B. L.,Zurawiecki, 
D.,Zwaigenbaum, L.,Betancur, C.,Buxbaum, J. D.,Cantor, R. M.,Cook, E. H.,Coon, 
H.,Cuccaro, M. L.,Gallagher, L.,Geschwind, D. H.,Gill, M.,Haines, J. L.,Miller, 
J.,Monaco, A. P.,Nurnberger, J. I., Jr.,Paterson, A. D.,Pericak-Vance, M. 
A.,Schellenberg, G. D.,Scherer, S. W.,Sutcliffe, J. S.,Szatmari, P.,Vicente, A. 
M.,Vieland, V. J.,Wijsman, E. M.,Devlin, B.,Ennis, S. & Hallmayer, J. (2010). A 
Genome-Wide Scan for Common Alleles Affecting Risk for Autism. Hum Mol Genet, 
Vol.19, No.20, Oct 15, pp.4072-4082,1460-2083     
Bardoni, B., Davidovic, L., Bensaid, M. & Khandjian, E. W. (2006). The Fragile X Syndrome: 
Exploring Its Molecular Basis and Seeking a Treatment. Expert Rev Mol Med, Vol.8, 
No.8, pp.1-16,1462-3994     
Bassell, G. J. & Warren, S. T. (2008). Fragile X Syndrome: Loss of Local Mrna Regulation 
Alters Synaptic Development and Function. Neuron, Vol.60, No.2, Oct 23, pp.201-
214,1097-4199     
Bauman, M. L. & Kemper, T. L. (2005). Neuroanatomic Observations of the Brain in Autism: 
A Review and Future Directions. Int J Dev Neurosci, Vol.23, No.2-3, Apr-May, 
pp.183-187,0736-5748     
Beffert, U., Weeber, E. J., Durudas, A., Qiu, S., Masiulis, I., Sweatt, J. D., Li, W. P., Adelmann, 
G., Frotscher, M., Hammer, R. E. & Herz, J. (2005). Modulation of Synaptic 
Plasticity and Memory by Reelin Involves Differential Splicing of the Lipoprotein 
Receptor Apoer2. Neuron, Vol.47, No.4, Aug 18, pp.567-579,0896-6273     
Ben-Ari, Y. (2002). Excitatory Actions of Gaba During Development: The Nature of the 
Nurture. Nat Rev Neurosci, Vol.3, No.9, Sep, pp.728-739,1471-003X     
Ben-Ari, Y. (2006). Seizures Beget Seizures: The Quest for Gaba as a Key Player. Crit Rev 
Neurobiol, Vol.18, No.1-2, pp.135-144,0892-0915     
Ben-Ari, Y. & Holmes, G. L. (2006). Effects of Seizures on Developmental Processes in the 
Immature Brain. Lancet Neurol, Vol.5, No.12, Dec, pp.1055-1063,1474-4422     
Benayed, R., Choi, J., Matteson, P. G., Gharani, N., Kamdar, S., Brzustowicz, L. M. & 
Millonig, J. H. (2009). Autism-Associated Haplotype Affects the Regulation of the 
Homeobox Gene, Engrailed 2. Biol Psychiatry, Vol.66, No.10, Nov 15, pp.911-
917,1873-2402     
Betancur, C. (2011). Etiological Heterogeneity in Autism Spectrum Disorders: More Than 
100 Genetic and Genomic Disorders and Still Counting. Brain Res, Vol.1380, Mar 22, 
pp.42-77,1872-6240     
Blatt, G. J., Fitzgerald, C. M., Guptill, J. T., Booker, A. B., Kemper, T. L. & Bauman, M. L. 
(2001). Density and Distribution of Hippocampal Neurotransmitter Receptors in 
www.intechopen.com
 
GABAergic Dysfunction in Autism and Epilepsy 
 
39 
Autism: An Autoradiographic Study. J Autism Dev Disord, Vol.31, No.6, Dec, 
pp.537-543,0162-3257     
Bombardieri, R., Pinci, M., Moavero, R., Cerminara, C. & Curatolo, P. (2010). Early Control 
of Seizures Improves Long-Term Outcome in Children with Tuberous Sclerosis 
Complex. Eur J Paediatr Neurol, Vol.14, No.2, Mar, pp.146-149,1532-2130     
Bradford, H. F. (1995). Glutamate, Gaba and Epilepsy. Prog Neurobiol, Vol.47, No.6, Dec, 
pp.477-511,0301-0082     
Brooks-Kayal, A. (2010). Epilepsy and Autism Spectrum Disorders: Are There Common 
Developmental Mechanisms? Brain Dev, Vol.32, No.9, Oct, pp.731-738,1872-7131     
Budreck, E. C. & Scheiffele, P. (2007). Neuroligin-3 Is a Neuronal Adhesion Protein at 
Gabaergic and Glutamatergic Synapses. Eur J Neurosci, Vol.26, No.7, Oct, pp.1738-
1748,0953-816X     
Buxbaum, J. D., Silverman, J. M., Smith, C. J., Greenberg, D. A., Kilifarski, M., Reichert, J., 
Cook, E. H., Jr., Fang, Y., Song, C. Y. & Vitale, R. (2002). Association between a 
Gabrb3 Polymorphism and Autism. Mol Psychiatry, Vol.7, No.3, pp.311-316,1359-
4184     
Canitano, R. (2007). Epilepsy in Autism Spectrum Disorders. Eur Child Adolesc Psychiatry, 
Vol.16, No.1, Feb, pp.61-66,1018-8827     
Carboni, G., Tueting, P., Tremolizzo, L., Sugaya, I., Davis, J., Costa, E. & Guidotti, A. (2004). 
Enhanced Dizocilpine Efficacy in Heterozygous Reeler Mice Relates to Gaba 
Turnover Downregulation. Neuropharmacology, Vol.46, No.8, Jun, pp.1070-
1081,0028-3908     
Casanova, M. & Trippe, J. (2009). Radial Cytoarchitecture and Patterns of Cortical 
Connectivity in Autism. Philos Trans R Soc Lond B Biol Sci, Vol.364, No.1522, May 27, 
pp.1433-1436,1471-2970     
Casanova, M. F., Buxhoeveden, D. & Gomez, J. (2003). Disruption in the Inhibitory 
Architecture of the Cell Minicolumn: Implications for Autisim. Neuroscientist, Vol.9, 
No.6, Dec, pp.496-507,1073-8584     
Casanova, M. F., Buxhoeveden, D. P., Switala, A. E. & Roy, E. (2002). Minicolumnar 
Pathology in Autism. Neurology, Vol.58, No.3, Feb 12, pp.428-432,0028-3878     
Centonze, D., Rossi, S., Mercaldo, V., Napoli, I., Ciotti, M. T., De Chiara, V., Musella, A., 
Prosperetti, C., Calabresi, P., Bernardi, G. & Bagni, C. (2008). Abnormal Striatal 
Gaba Transmission in the Mouse Model for the Fragile X Syndrome. Biol Psychiatry, 
Vol.63, No.10, May 15, pp.963-973,1873-2402     
Chahrour, M. & Zoghbi, H. Y. (2007). The Story of Rett Syndrome: From Clinic to 
Neurobiology. Neuron, Vol.56, No.3, Nov 8, pp.422-437,0896-6273     
Chang, S. C., Pauls, D. L., Lange, C., Sasanfar, R. & Santangelo, S. L. (2010). Common 
Genetic Variation in the Gad1 Gene and the Entire Family of Dlx Homeobox Genes 
and Autism Spectrum Disorders. Am J Med Genet B Neuropsychiatr Genet, Dec 
16,1552-485X     
Chao, H. T., Chen, H., Samaco, R. C., Xue, M., Chahrour, M., Yoo, J., Neul, J. L., Gong, S., Lu, 
H. C., Heintz, N., Ekker, M., Rubenstein, J. L., Noebels, J. L., Rosenmund, C. & 
Zoghbi, H. Y. (2010). Dysfunction in Gaba Signalling Mediates Autism-Like 
Stereotypies and Rett Syndrome Phenotypes. Nature, Vol.468, No.7321, Nov 11, 
pp.263-269,1476-4687     
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
40
Cheh, M. A., Millonig, J. H., Roselli, L. M., Ming, X., Jacobsen, E., Kamdar, S. & Wagner, G. 
C. (2006). En2 Knockout Mice Display Neurobehavioral and Neurochemical 
Alterations Relevant to Autism Spectrum Disorder. Brain Res, Vol.1116, No.1, Oct 
20, pp.166-176,0006-8993     
Chen, L. & Toth, M. (2001). Fragile X Mice Develop Sensory Hyperreactivity to Auditory 
Stimuli. Neuroscience, Vol.103, No.4, pp.1043-1050,0306-4522     
Chih, B., Engelman, H. & Scheiffele, P. (2005). Control of Excitatory and Inhibitory Synapse 
Formation by Neuroligins. Science, Vol.307, No.5713, Feb 25, pp.1324-1328,1095-
9203     
Chin, R. F., Neville, B. G., Peckham, C., Bedford, H., Wade, A. & Scott, R. C. (2006). 
Incidence, Cause, and Short-Term Outcome of Convulsive Status Epilepticus in 
Childhood: Prospective Population-Based Study. Lancet, Vol.368, No.9531, Jul 15, 
pp.222-229,1474-547X     
Cobos, I., Calcagnotto, M. E., Vilaythong, A. J., Thwin, M. T., Noebels, J. L., Baraban, S. C. & 
Rubenstein, J. L. (2005). Mice Lacking Dlx1 Show Subtype-Specific Loss of 
Interneurons, Reduced Inhibition and Epilepsy. Nat Neurosci, Vol.8, No.8, Aug, 
pp.1059-1068,1097-6256     
Collins, A. L., Ma, D., Whitehead, P. L., Martin, E. R., Wright, H. H., Abramson, R. K., 
Hussman, J. P., Haines, J. L., Cuccaro, M. L., Gilbert, J. R. & Pericak-Vance, M. A. 
(2006). Investigation of Autism and Gaba Receptor Subunit Genes in Multiple 
Ethnic Groups. Neurogenetics, Vol.7, No.3, Jul, pp.167-174,1364-6745     
Craig, A. M. & Kang, Y. (2007). Neurexin-Neuroligin Signaling in Synapse Development. 
Curr Opin Neurobiol, Vol.17, No.1, Feb, pp.43-52,0959-4388     
Curia, G., Papouin, T., Seguela, P. & Avoli, M. (2009). Downregulation of Tonic Gabaergic 
Inhibition in a Mouse Model of Fragile X Syndrome. Cereb Cortex, Vol.19, No.7, Jul, 
pp.1515-1520,1460-2199     
Curran, T. & D'Arcangelo, G. (1998). Role of Reelin in the Control of Brain Development. 
Brain Res Brain Res Rev, Vol.26, No.2-3, May, pp.285-294 
D'Hulst, C., Heulens, I., Brouwer, J. R., Willemsen, R., De Geest, N., Reeve, S. P., De Deyn, P. 
P., Hassan, B. A. & Kooy, R. F. (2009). Expression of the Gabaergic System in 
Animal Models for Fragile X Syndrome and Fragile X Associated Tremor/Ataxia 
Syndrome (Fxtas). Brain Res, Vol.1253, Feb 9, pp.176-183,1872-6240     
D'Hulst, C. & Kooy, R. F. (2007). The Gabaa Receptor: A Novel Target for Treatment of 
Fragile X? Trends Neurosci, Vol.30, No.8, Aug, pp.425-431,0166-2236     
D'Hulst, C. & Kooy, R. F. (2009). Fragile X Syndrome: From Molecular Genetics to Therapy. J 
Med Genet, Vol.46, No.9, Sep, pp.577-584,1468-6244     
Danielsson, S., Gillberg, I. C., Billstedt, E., Gillberg, C. & Olsson, I. (2005). Epilepsy in Young 
Adults with Autism: A Prospective Population-Based Follow-up Study of 120 
Individuals Diagnosed in Childhood. Epilepsia, Vol.46, No.6, Jun, pp.918-923,0013-
9580     
DeFelipe, J., Hendry, S. H., Hashikawa, T., Molinari, M. & Jones, E. G. (1990). A 
Microcolumnar Structure of Monkey Cerebral Cortex Revealed by 
Immunocytochemical Studies of Double Bouquet Cell Axons. Neuroscience, Vol.37, 
No.3, pp.655-673,0306-4522     
DeLorey, T. M., Handforth, A., Anagnostaras, S. G., Homanics, G. E., Minassian, B. A., 
Asatourian, A., Fanselow, M. S., Delgado-Escueta, A., Ellison, G. D. & Olsen, R. W. 
www.intechopen.com
 
GABAergic Dysfunction in Autism and Epilepsy 
 
41 
(1998). Mice Lacking the Beta3 Subunit of the Gabaa Receptor Have the Epilepsy 
Phenotype and Many of the Behavioral Characteristics of Angelman Syndrome. J 
Neurosci, Vol.18, No.20, Oct 15, pp.8505-8514,0270-6474     
DeLorey, T. M., Sahbaie, P., Hashemi, E., Homanics, G. E. & Clark, J. D. (2008). Gabrb3 Gene 
Deficient Mice Exhibit Impaired Social and Exploratory Behaviors, Deficits in Non-
Selective Attention and Hypoplasia of Cerebellar Vermal Lobules: A Potential 
Model of Autism Spectrum Disorder. Behav Brain Res, Vol.187, No.2, Mar 5, pp.207-
220,0166-4328     
Depositario-Cabacar, D. F. & Zelleke, T. G. (2010). Treatment of Epilepsy in Children with 
Developmental Disabilities. Dev Disabil Res Rev, Vol.16, No.3, pp.239-247,1940-5529     
DeSilva, U., D'Arcangelo, G., Braden, V. V., Chen, J., Miao, G. G., Curran, T. & Green, E. D. 
(1997). The Human Reelin Gene: Isolation, Sequencing, and Mapping on 
Chromosome 7. Genome Res, Vol.7, No.2, Feb, pp.157-164,1088-9051     
Di Cristo, G. (2007). Development of Cortical Gabaergic Circuits and Its Implications for 
Neurodevelopmental Disorders. Clin Genet, Vol.72, No.1, Jul, pp.1-8,0009-9163     
Dunleavy, M., Shinoda, S., Schindler, C., Ewart, C., Dolan, R., Gobbo, O. L., Kerskens, C. M. 
& Henshall, D. C. (2010). Experimental Neonatal Status Epilepticus and the 
Development of Temporal Lobe Epilepsy with Unilateral Hippocampal Sclerosis. 
Am J Pathol, Vol.176, No.1, Jan, pp.330-342,1525-2191     
El Idrissi, A., Ding, X. H., Scalia, J., Trenkner, E., Brown, W. T. & Dobkin, C. (2005). 
Decreased Gaba(a) Receptor Expression in the Seizure-Prone Fragile X Mouse. 
Neurosci Lett, Vol.377, No.3, Apr 4, pp.141-146,0304-3940     
Enticott, P. G., Rinehart, N. J., Tonge, B. J., Bradshaw, J. L. & Fitzgerald, P. B. (2010). A 
Preliminary Transcranial Magnetic Stimulation Study of Cortical Inhibition and 
Excitability in High-Functioning Autism and Asperger Disorder. Dev Med Child 
Neurol, Vol.52, No.8, Aug, pp.e179-e183,0012-1622 
Fatemi, S. H., Halt, A. R., Stary, J. M., Kanodia, R., Schulz, S. C. & Realmuto, G. R. (2002). 
Glutamic Acid Decarboxylase 65 and 67 Kda Proteins Are Reduced in Autistic 
Parietal and Cerebellar Cortices. Biol Psychiatry, Vol.52, No.8, Oct 15, pp.805-
810,0006-3223     
Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Rooney, R. J., Patel, D. H. & Thuras, P. D. (2010). 
Mrna and Protein Levels for Gabaaalpha4, Alpha5, Beta1 and Gababr1 Receptors 
Are Altered in Brains from Subjects with Autism. J Autism Dev Disord, Vol.40, No.6, 
Jun, pp.743-750,1573-3432     
Fatemi, S. H., Snow, A. V., Stary, J. M., Araghi-Niknam, M., Reutiman, T. J., Lee, S., Brooks, 
A. I. & Pearce, D. A. (2005). Reelin Signaling Is Impaired in Autism. Biol Psychiatry, 
Vol.57, No.7, Apr 1, pp.777-787,0006-3223     
Feng, J., Schroer, R., Yan, J., Song, W., Yang, C., Bockholt, A., Cook, E. H., Jr., Skinner, C., 
Schwartz, C. E. & Sommer, S. S. (2006). High Frequency of Neurexin 1beta Signal 
Peptide Structural Variants in Patients with Autism. Neurosci Lett, Vol.409, No.1, 
Nov 27, pp.10-13,0304-3940     
Fombonne, E. (2009). Epidemiology of Pervasive Developmental Disorders. Pediatr Res, 
Vol.65, No.6, Jun, pp.591-598,1530-0447     
Forster, E., Tielsch, A., Saum, B., Weiss, K. H., Johanssen, C., Graus-Porta, D., Muller, U. & 
Frotscher, M. (2002). Reelin, Disabled 1, and Beta 1 Integrins Are Required for the 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
42
Formation of the Radial Glial Scaffold in the Hippocampus. Proc Natl Acad Sci U S 
A, Vol.99, No.20, Oct 1, pp.13178-13183,0027-8424     
Freitag, C. M. (2007). The Genetics of Autistic Disorders and Its Clinical Relevance: A 
Review of the Literature. Mol Psychiatry, Vol.12, No.1, Jan, pp.2-22,1359-4184     
Gant, J. C., Thibault, O., Blalock, E. M., Yang, J., Bachstetter, A., Kotick, J., Schauwecker, P. 
E., Hauser, K. F., Smith, G. M., Mervis, R., Li, Y. & Barnes, G. N. (2009). Decreased 
Number of Interneurons and Increased Seizures in Neuropilin 2 Deficient Mice: 
Implications for Autism and Epilepsy. Epilepsia, Vol.50, No.4, Apr, pp.629-645,1528-
1167     
Gauthey, M., Poloni, C. B., Ramelli, G. P., Roulet-Perez, E. & Korff, C. M. (2010). Status 
Epilepticus in Fragile X Syndrome. Epilepsia, Vol.51, No.12, Dec, pp.2470-2473,1528-
1167     
Gogolla, N., Leblanc, J. J., Quast, K. B., Sudhof, T., Fagiolini, M. & Hensch, T. K. (2009). 
Common Circuit Defect of Excitatory-Inhibitory Balance in Mouse Models of 
Autism. J Neurodev Disord, Vol.1, No.2, Jun 1, pp.172-181,1866-1947     
Graf, E. R., Zhang, X., Jin, S. X., Linhoff, M. W. & Craig, A. M. (2004). Neurexins Induce 
Differentiation of Gaba and Glutamate Postsynaptic Specializations Via 
Neuroligins. Cell, Vol.119, No.7, Dec 29, pp.1013-1026,0092-8674     
Hara, H. (2007). Autism and Epilepsy: A Retrospective Follow-up Study. Brain Dev, Vol.29, 
No.8, Sep, pp.486-490,0387-7604     
Hatton, D. D., Sideris, J., Skinner, M., Mankowski, J., Bailey, D. B., Jr., Roberts, J. & Mirrett, 
P. (2006). Autistic Behavior in Children with Fragile X Syndrome: Prevalence, 
Stability, and the Impact of Fmrp. Am J Med Genet A, Vol.140A, No.17, Sep 1, 
pp.1804-1813,1552-4825     
Hauser, W. A. (1990). Status Epilepticus: Epidemiologic Considerations. Neurology, Vol.40, 
No.5 Suppl 2, May, pp.9-13,0028-3878     
Hogart, A., Leung, K. N., Wang, N. J., Wu, D. J., Driscoll, J., Vallero, R. O., Schanen, N. C. & 
LaSalle, J. M. (2009). Chromosome 15q11-13 Duplication Syndrome Brain Reveals 
Epigenetic Alterations in Gene Expression Not Predicted from Copy Number. J 
Med Genet, Vol.46, No.2, Feb, pp.86-93,1468-6244     
Hogart, A., Nagarajan, R. P., Patzel, K. A., Yasui, D. H. & Lasalle, J. M. (2007). 15q11-13 
Gabaa Receptor Genes Are Normally Biallelically Expressed in Brain yet Are 
Subject to Epigenetic Dysregulation in Autism-Spectrum Disorders. Hum Mol Genet, 
Vol.16, No.6, Mar 15, pp.691-703,0964-6906     
Homanics, G. E., DeLorey, T. M., Firestone, L. L., Quinlan, J. J., Handforth, A., Harrison, N. 
L., Krasowski, M. D., Rick, C. E., Korpi, E. R., Makela, R., Brilliant, M. H., 
Hagiwara, N., Ferguson, C., Snyder, K. & Olsen, R. W. (1997). Mice Devoid of 
Gamma-Aminobutyrate Type a Receptor Beta3 Subunit Have Epilepsy, Cleft 
Palate, and Hypersensitive Behavior. Proc Natl Acad Sci U S A, Vol.94, No.8, Apr 15, 
pp.4143-4148,0027-8424     
Jamain, S., Quach, H., Betancur, C., Rastam, M., Colineaux, C., Gillberg, I. C., Soderstrom, 
H., Giros, B., Leboyer, M., Gillberg, C. & Bourgeron, T. (2003). Mutations of the X-
Linked Genes Encoding Neuroligins Nlgn3 and Nlgn4 Are Associated with 
Autism. Nat Genet, Vol.34, No.1, May, pp.27-29,1061-4036     
Jensen, F. E. (2011). Epilepsy as a Spectrum Disorder: Implications from Novel Clinical and 
Basic Neuroscience. Epilepsia, Vol.52 Suppl 1, Jan, pp.1-6,1528-1167     
www.intechopen.com
 
GABAergic Dysfunction in Autism and Epilepsy 
 
43 
Jian, L., Nagarajan, L., de Klerk, N., Ravine, D., Bower, C., Anderson, A., Williamson, S., 
Christodoulou, J. & Leonard, H. (2006). Predictors of Seizure Onset in Rett 
Syndrome. J Pediatr, Vol.149, No.4, Oct, pp.542-547,0022-3476     
Joyner, A. L., Herrup, K., Auerbach, B. A., Davis, C. A. & Rossant, J. (1991). Subtle Cerebellar 
Phenotype in Mice Homozygous for a Targeted Deletion of the En-2 Homeobox. 
Science, Vol.251, No.4998, Mar 8, pp.1239-1243,0036-8075     
Karlsen, A. E., Hagopian, W. A., Grubin, C. E., Dube, S., Disteche, C. M., Adler, D. A., 
Barmeier, H., Mathewes, S., Grant, F. J., Foster, D. & et al. (1991). Cloning and 
Primary Structure of a Human Islet Isoform of Glutamic Acid Decarboxylase from 
Chromosome 10. Proc Natl Acad Sci U S A, Vol.88, No.19, Oct 1, pp.8337-8341,0027-
8424     
Kash, S. F., Johnson, R. S., Tecott, L. H., Noebels, J. L., Mayfield, R. D., Hanahan, D. & 
Baekkeskov, S. (1997). Epilepsy in Mice Deficient in the 65-Kda Isoform of Glutamic 
Acid Decarboxylase. Proc Natl Acad Sci U S A, Vol.94, No.25, Dec 9, pp.14060-
14065,0027-8424     
Kaufman, D. L., Houser, C. R. & Tobin, A. J. (1991). Two Forms of the Gamma-
Aminobutyric Acid Synthetic Enzyme Glutamate Decarboxylase Have Distinct 
Intraneuronal Distributions and Cofactor Interactions. J Neurochem, Vol.56, No.2, 
Feb, pp.720-723,0022-3042     
Kemper, T. L. & Bauman, M. L. (1993). The Contribution of Neuropathologic Studies to the 
Understanding of Autism. Neurol Clin, Vol.11, No.1, Feb, pp.175-187,0733-8619     
Kim, H. G., Kishikawa, S., Higgins, A. W., Seong, I. S., Donovan, D. J., Shen, Y., Lally, E., 
Weiss, L. A., Najm, J., Kutsche, K., Descartes, M., Holt, L., Braddock, S., Troxell, R., 
Kaplan, L., Volkmar, F., Klin, A., Tsatsanis, K., Harris, D. J., Noens, I., Pauls, D. L., 
Daly, M. J., MacDonald, M. E., Morton, C. C., Quade, B. J. & Gusella, J. F. (2008). 
Disruption of Neurexin 1 Associated with Autism Spectrum Disorder. Am J Hum 
Genet, Vol.82, No.1, Jan, pp.199-207,1537-6605     
Kuemerle, B., Zanjani, H., Joyner, A. & Herrup, K. (1997). Pattern Deformities and Cell Loss 
in Engrailed-2 Mutant Mice Suggest Two Separate Patterning Events During 
Cerebellar Development. J Neurosci, Vol.17, No.20, Oct 15, pp.7881-7889,0270-6474     
Laumonnier, F., Bonnet-Brilhault, F., Gomot, M., Blanc, R., David, A., Moizard, M. P., 
Raynaud, M., Ronce, N., Lemonnier, E., Calvas, P., Laudier, B., Chelly, J., Fryns, J. 
P., Ropers, H. H., Hamel, B. C., Andres, C., Barthelemy, C., Moraine, C. & Briault, S. 
(2004). X-Linked Mental Retardation and Autism Are Associated with a Mutation 
in the Nlgn4 Gene, a Member of the Neuroligin Family. Am J Hum Genet, Vol.74, 
No.3, Mar, pp.552-557,0002-9297     
Laurvick, C. L., De Klerk, N., Bower, C., Christodoulou, J., Ravine, D., Ellaway, C., 
Williamson, S. & Leonard, H. (2006). Rett Syndrome in Australia: A Review of the 
Epidemiology. Journal of Pediatrics, Vol.148, No.3, Mar, pp.347-352,0022-3476 
Lawrence, Y. A., Kemper, T. L., Bauman, M. L. & Blatt, G. J. (2010). Parvalbumin-, 
Calbindin-, and Calretinin-Immunoreactive Hippocampal Interneuron Density in 
Autism. Acta Neurol Scand, Vol.121, No.2, Feb, pp.99-108,1600-0404     
Lawson-Yuen, A., Saldivar, J. S., Sommer, S. & Picker, J. (2008). Familial Deletion within 
Nlgn4 Associated with Autism and Tourette Syndrome. Eur J Hum Genet, Vol.16, 
No.5, May, pp.614-618,1018-4813       
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
44
Li, H., Kraus, A., Wu, J., Huguenard, J. R. & Fisher, R. S. (2006). Selective Changes in 
Thalamic and Cortical Gabaa Receptor Subunits in a Model of Acquired Absence 
Epilepsy in the Rat. Neuropharmacology, Vol.51, No.1, Jul, pp.121-128,0028-3908     
Liljelund, P., Handforth, A., Homanics, G. E. & Olsen, R. W. (2005). Gabaa Receptor Beta3 
Subunit Gene-Deficient Heterozygous Mice Show Parent-of-Origin and Gender-
Related Differences in Beta3 Subunit Levels, Eeg, and Behavior. Brain Res Dev Brain 
Res, Vol.157, No.2, Jun 30, pp.150-161,0165-3806     
Lintas, C. & Persico, A. M. (2009). Autistic Phenotypes and Genetic Testing: State-of-the-Art 
for the Clinical Geneticist. J Med Genet, Vol.46, No.1, Jan, pp.1-8,1468-6244     
Liu, X., Novosedlik, N., Wang, A., Hudson, M. L., Cohen, I. L., Chudley, A. E., Forster-
Gibson, C. J., Lewis, S. M. & Holden, J. J. (2009). The Dlx1and Dlx2 Genes and 
Susceptibility to Autism Spectrum Disorders. Eur J Hum Genet, Vol.17, No.2, Feb, 
pp.228-235,1476-5438     
Loring, D. W., Marino, S. & Meador, K. J. (2007). Neuropsychological and Behavioral Effects 
of Antiepilepsy Drugs. Neuropsychol Rev, Vol.17, No.4, Dec, pp.413-425,1040-7308     
Loup, F., Picard, F., Andre, V. M., Kehrli, P., Yonekawa, Y., Wieser, H. G. & Fritschy, J. M. 
(2006). Altered Expression of Alpha3-Containing Gabaa Receptors in the Neocortex 
of Patients with Focal Epilepsy. Brain, Vol.129, No.Pt 12, Dec, pp.3277-3289,1460-
2156     
Loup, F., Wieser, H. G., Yonekawa, Y., Aguzzi, A. & Fritschy, J. M. (2000). Selective 
Alterations in Gabaa Receptor Subtypes in Human Temporal Lobe Epilepsy. J 
Neurosci, Vol.20, No.14, Jul 15, pp.5401-5419,0270-6474     
Lowenstein, D. H. (2006). The Management of Refractory Status Epilepticus: An Update. 
Epilepsia, Vol.47 Suppl 1, pp.35-40,0013-9580     
Macri, S., Biamonte, F., Romano, E., Marino, R., Keller, F. & Laviola, G. (2010). Perseverative 
Responding and Neuroanatomical Alterations in Adult Heterozygous Reeler Mice 
Are Mitigated by Neonatal Estrogen Administration. Psychoneuroendocrinology, 
Vol.35, No.9, Oct, pp.1374-1387,1873-3360 
Mao, R., Page, D. T., Merzlyak, I., Kim, C., Tecott, L. H., Janak, P. H., Rubenstein, J. L. & Sur, 
M. (2009). Reduced Conditioned Fear Response in Mice That Lack Dlx1 and Show 
Subtype-Specific Loss of Interneurons. J Neurodev Disord, Vol.1, No.3, Sep, pp.224-
236,1866-1947     
Martin, D. L. & Rimvall, K. (1993). Regulation of Gamma-Aminobutyric Acid Synthesis in 
the Brain. J Neurochem, Vol.60, No.2, Feb, pp.395-407,0022-3042     
Mountcastle, V. B. (1997). The Columnar Organization of the Neocortex. Brain, Vol.120 ( Pt 
4), Apr, pp.701-722,0006-8950       
Musumeci, S. A., Bosco, P., Calabrese, G., Bakker, C., De Sarro, G. B., Elia, M., Ferri, R. & 
Oostra, B. A. (2000). Audiogenic Seizures Susceptibility in Transgenic Mice with 
Fragile X Syndrome. Epilepsia, Vol.41, No.1, Jan, pp.19-23,0013-9580     
Musumeci, S. A., Calabrese, G., Bonaccorso, C. M., D'Antoni, S., Brouwer, J. R., Bakker, C. E., 
Elia, M., Ferri, R., Nelson, D. L., Oostra, B. A. & Catania, M. V. (2007). Audiogenic 
Seizure Susceptibility Is Reduced in Fragile X Knockout Mice after Introduction of 
Fmr1 Transgenes. Exp Neurol, Vol.203, No.1, Jan, pp.233-240,0014-4886     
Oblak, A. L., Gibbs, T. T. & Blatt, G. J. (2010). Decreased Gaba(B) Receptors in the Cingulate 
Cortex and Fusiform Gyrus in Autism. J Neurochem, Vol.114, No.5, Sep 1, pp.1414-
1423,1471-4159     
www.intechopen.com
 
GABAergic Dysfunction in Autism and Epilepsy 
 
45 
Oblak, A. L., Gibbs, T. T. & Blatt, G. J. (2011). Reduced Gaba(a) Receptors and 
Benzodiazepine Binding Sites in the Posterior Cingulate Cortex and Fusiform 
Gyrus in Autism. Brain Res, Vol.1380, Mar 22, pp.218-228,1872-6240     
Olmos-Serrano, J. L., Paluszkiewicz, S. M., Martin, B. S., Kaufmann, W. E., Corbin, J. G. & 
Huntsman, M. M. (2010). Defective Gabaergic Neurotransmission and 
Pharmacological Rescue of Neuronal Hyperexcitability in the Amygdala in a 
Mouse Model of Fragile X Syndrome. J Neurosci, Vol.30, No.29, Jul 21, pp.9929-
9938,1529-2401     
Olsen, R. W. & Avoli, M. (1997). Gaba and Epileptogenesis. Epilepsia, Vol.38, No.4, Apr, 
pp.399-407,0013-9580       
Olsen, R. W. & Sieghart, W. (2009). Gaba a Receptors: Subtypes Provide Diversity of 
Function and Pharmacology. Neuropharmacology, Vol.56, No.1, Jan, pp.141-148,0028-
3908     
Persico, A. M. & Bourgeron, T. (2006). Searching for Ways out of the Autism Maze: Genetic, 
Epigenetic and Environmental Clues. Trends Neurosci, Vol.29, No.7, Jul, pp.349-
358,0166-2236     
Persico, A. M., D'Agruma, L., Maiorano, N., Totaro, A., Militerni, R., Bravaccio, C., Wassink, 
T. H., Schneider, C., Melmed, R., Trillo, S., Montecchi, F., Palermo, M., Pascucci, T., 
Puglisi-Allegra, S., Reichelt, K. L., Conciatori, M., Marino, R., Quattrocchi, C. C., 
Baldi, A., Zelante, L., Gasparini, P. & Keller, F. (2001). Reelin Gene Alleles and 
Haplotypes as a Factor Predisposing to Autistic Disorder. Mol Psychiatry, Vol.6, 
No.2, Mar, pp.150-159,1359-4184     
Pirker, S., Schwarzer, C., Czech, T., Baumgartner, C., Pockberger, H., Maier, H., Hauer, B., 
Sieghart, W., Furtinger, S. & Sperk, G. (2003). Increased Expression of Gaba(a) 
Receptor Beta-Subunits in the Hippocampus of Patients with Temporal Lobe 
Epilepsy. J Neuropathol Exp Neurol, Vol.62, No.8, Aug, pp.820-834,0022-3069     
Pleasure, S. J., Anderson, S., Hevner, R., Bagri, A., Marin, O., Lowenstein, D. H. & 
Rubenstein, J. L. (2000). Cell Migration from the Ganglionic Eminences Is Required 
for the Development of Hippocampal Gabaergic Interneurons. Neuron, Vol.28, 
No.3, Dec, pp.727-740,0896-6273     
Polleux, F. & Lauder, J. M. (2004). Toward a Developmental Neurobiology of Autism. Ment 
Retard Dev Disabil Res Rev, Vol.10, No.4, pp.303-317,1080-4013     
Radyushkin, K., Hammerschmidt, K., Boretius, S., Varoqueaux, F., El-Kordi, A., 
Ronnenberg, A., Winter, D., Frahm, J., Fischer, J., Brose, N. & Ehrenreich, H. (2009). 
Neuroligin-3-Deficient Mice: Model of a Monogenic Heritable Form of Autism with 
an Olfactory Deficit. Genes Brain Behav, Vol.8, No.4, Jun, pp.416-425,1601-183X     
Raghanti, M. A., Spocter, M. A., Butti, C., Hof, P. R. & Sherwood, C. C. (2010). A 
Comparative Perspective on Minicolumns and Inhibitory Gabaergic Interneurons 
in the Neocortex. Front Neuroanat, Vol.4, pp.3,1662-5129     
Raspall-Chaure, M., Chin, R. F., Neville, B. G. & Scott, R. C. (2006). Outcome of Paediatric 
Convulsive Status Epilepticus: A Systematic Review. Lancet Neurol, Vol.5, No.9, 
Sep, pp.769-779,1474-4422     
Rubenstein, J. L. & Merzenich, M. M. (2003). Model of Autism: Increased Ratio of 
Excitation/Inhibition in Key Neural Systems. Genes Brain Behav, Vol.2, No.5, Oct, 
pp.255-267,1601-1848     
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
46
Rudy, B., Fishell, G., Lee, S. & Hjerling-Leffler, J. (2010). Three Groups of Interneurons 
Account for Nearly 100% of Neocortical Gabaergic Neurons. Dev Neurobiol, Nov 
30,1932-846X     
Sabaratnam, M. (2000). Pathological and Neuropathological Findings in Two Males with 
Fragile-X Syndrome. J Intellect Disabil Res, Vol.44 ( Pt 1), Feb, pp.81-85,0964-2633     
Samaco, R. C., Hogart, A. & LaSalle, J. M. (2005). Epigenetic Overlap in Autism-Spectrum 
Neurodevelopmental Disorders: Mecp2 Deficiency Causes Reduced Expression of 
Ube3a and Gabrb3. Hum Mol Genet, Vol.14, No.4, Feb 15, pp.483-492,0964-6906     
Scheiffele, P., Fan, J., Choih, J., Fetter, R. & Serafini, T. (2000). Neuroligin Expressed in 
Nonneuronal Cells Triggers Presynaptic Development in Contacting Axons. Cell, 
Vol.101, No.6, Jun 9, pp.657-669,0092-8674     
Schroer, R. J., Phelan, M. C., Michaelis, R. C., Crawford, E. C., Skinner, S. A., Cuccaro, M., 
Simensen, R. J., Bishop, J., Skinner, C., Fender, D. & Stevenson, R. E. (1998). Autism 
and Maternally Derived Aberrations of Chromosome 15q. Am J Med Genet, Vol.76, 
No.4, Apr 1, pp.327-336,0148-7299     
Selby, L., Zhang, C. & Sun, Q. Q. (2007). Major Defects in Neocortical Gabaergic Inhibitory 
Circuits in Mice Lacking the Fragile X Mental Retardation Protein. Neurosci Lett, 
Vol.412, No.3, Feb 2, pp.227-232,0304-3940     
Steffenburg, U., Hagberg, G. & Hagberg, B. (2001). Epilepsy in a Representative Series of 
Rett Syndrome. Acta Paediatr, Vol.90, No.1, Jan, pp.34-39,0803-5253     
Stork, O., Ji, F. Y., Kaneko, K., Stork, S., Yoshinobu, Y., Moriya, T., Shibata, S. & Obata, K. 
(2000). Postnatal Development of a Gaba Deficit and Disturbance of Neural 
Functions in Mice Lacking Gad65. Brain Res, Vol.865, No.1, May 19, pp.45-58,0006-
8993     
Tabuchi, K., Blundell, J., Etherton, M. R., Hammer, R. E., Liu, X., Powell, C. M. & Sudhof, T. 
C. (2007). A Neuroligin-3 Mutation Implicated in Autism Increases Inhibitory 
Synaptic Transmission in Mice. Science, Vol.318, No.5847, Oct 5, pp.71-76,1095-9203     
Toro, R., Konyukh, M., Delorme, R., Leblond, C., Chaste, P., Fauchereau, F., Coleman, M., 
Leboyer, M., Gillberg, C. & Bourgeron, T. (2010). Key Role for Gene Dosage and 
Synaptic Homeostasis in Autism Spectrum Disorders. Trends Genet, Vol.26, No.8, 
Aug, pp.363-372,0168-9525     
Treiman, D. M., Meyers, P. D., Walton, N. Y., Collins, J. F., Colling, C., Rowan, A. J., 
Handforth, A., Faught, E., Calabrese, V. P., Uthman, B. M., Ramsay, R. E. & 
Mamdani, M. B. (1998). A Comparison of Four Treatments for Generalized 
Convulsive Status Epilepticus. Veterans Affairs Status Epilepticus Cooperative 
Study Group. N Engl J Med, Vol.339, No.12, Sep 17, pp.792-798,0028-4793     
Tripathi, P. P., Sgado, P., Scali, M., Viaggi, C., Casarosa, S., Simon, H. H., Vaglini, F., Corsini, 
G. U. & Bozzi, Y. (2009). Increased Susceptibility to Kainic Acid-Induced Seizures in 
Engrailed-2 Knockout Mice. Neuroscience, Vol.159, No.2, Mar 17, pp.842-849,0306-
4522     
Tuchman, R. (2000). Treatment of Seizure Disorders and Eeg Abnormalities in Children with 
Autism Spectrum Disorders. J Autism Dev Disord, Vol.30, No.5, Oct, pp.485-
489,0162-3257     
Tuchman, R., Moshe, S. L. & Rapin, I. (2009). Convulsing toward the Pathophysiology of 
Autism. Brain Dev, Vol.31, No.2, Feb, pp.95-103,1872-7131     
www.intechopen.com
 
GABAergic Dysfunction in Autism and Epilepsy 
 
47 
Urak, L., Feucht, M., Fathi, N., Hornik, K. & Fuchs, K. (2006). A Gabrb3 Promoter Haplotype 
Associated with Childhood Absence Epilepsy Impairs Transcriptional Activity. 
Hum Mol Genet, Vol.15, No.16, Aug 15, pp.2533-2541,0964-6906     
van Kooten, I.A.J., Hof, P.R., van Engeland, H., Steinbusch, H.W.M., Patterson, P.H., & 
Schmitz, C. (2005). Autism: Neuropathology, Alterations of the GABAergic System, 
and Animal Models, In: International Review of Neurobiology. Vol. 71, pp. 2-17, 
Elsevier Inc., 0074-7742 
Varoqueaux, F., Aramuni, G., Rawson, R. L., Mohrmann, R., Missler, M., Gottmann, K., 
Zhang, W., Sudhof, T. C. & Brose, N. (2006). Neuroligins Determine Synapse 
Maturation and Function. Neuron, Vol.51, No.6, Sep 21, pp.741-754,0896-6273     
Verkerk, A. J., Pieretti, M., Sutcliffe, J. S., Fu, Y. H., Kuhl, D. P., Pizzuti, A., Reiner, O., 
Richards, S., Victoria, M. F., Zhang, F. P. & et al. (1991). Identification of a Gene 
(Fmr-1) Containing a Cgg Repeat Coincident with a Breakpoint Cluster Region 
Exhibiting Length Variation in Fragile X Syndrome. Cell, Vol.65, No.5, May 31, 
pp.905-914,0092-8674     
Volkmar, F. R. & Nelson, D. S. (1990). Seizure Disorders in Autism. J Am Acad Child Adolesc 
Psychiatry, Vol.29, No.1, Jan, pp.127-129,0890-8567     
Vorstman, J. A., Staal, W. G., van Daalen, E., van Engeland, H., Hochstenbach, P. F. & 
Franke, L. (2006). Identification of Novel Autism Candidate Regions through 
Analysis of Reported Cytogenetic Abnormalities Associated with Autism. Mol 
Psychiatry, Vol.11, No.1, Jan, pp.1, 18-28,1359-4184     
Wang, K., Zhang, H., Ma, D., Bucan, M., Glessner, J. T., Abrahams, B. S., Salyakina, D., 
Imielinski, M., Bradfield, J. P., Sleiman, P. M., Kim, C. E., Hou, C., Frackelton, E., 
Chiavacci, R., Takahashi, N., Sakurai, T., Rappaport, E., Lajonchere, C. M., Munson, 
J., Estes, A., Korvatska, O., Piven, J., Sonnenblick, L. I., Alvarez Retuerto, A. I., 
Herman, E. I., Dong, H., Hutman, T., Sigman, M., Ozonoff, S., Klin, A., Owley, T., 
Sweeney, J. A., Brune, C. W., Cantor, R. M., Bernier, R., Gilbert, J. R., Cuccaro, M. L., 
McMahon, W. M., Miller, J., State, M. W., Wassink, T. H., Coon, H., Levy, S. E., 
Schultz, R. T., Nurnberger, J. I., Haines, J. L., Sutcliffe, J. S., Cook, E. H., Minshew, 
N. J., Buxbaum, J. D., Dawson, G., Grant, S. F., Geschwind, D. H., Pericak-Vance, M. 
A., Schellenberg, G. D. & Hakonarson, H. (2009). Common Genetic Variants on 
5p14.1 Associate with Autism Spectrum Disorders. Nature, Vol.459, No.7246, May 
28, pp.528-533,1476-4687     
Weiss, L. A., Arking, D. E., Daly, M. J. & Chakravarti, A. (2009). A Genome-Wide Linkage 
and Association Scan Reveals Novel Loci for Autism. Nature, Vol.461, No.7265, Oct 
8, pp.802-808,1476-4687     
Whitney, E. R., Kemper, T. L., Rosene, D. L., Bauman, M. L. & Blatt, G. J. (2008). Calbindin-
D28k Is a More Reliable Marker of Human Purkinje Cells Than Standard Nissl 
Stains: A Stereological Experiment. J Neurosci Methods, Vol.168, No.1, Feb 15, pp.42-
47,0165-0270     
Whitney, E. R., Kemper, T. L., Rosene, D. L., Bauman, M. L. & Blatt, G. J. (2009). Density of 
Cerebellar Basket and Stellate Cells in Autism: Evidence for a Late Developmental 
Loss of Purkinje Cells. J Neurosci Res, Vol.87, No.10, Aug 1, pp.2245-2254,1097-4547     
Wisniowiecka-Kowalnik, B., Nesteruk, M., Peters, S. U., Xia, Z., Cooper, M. L., Savage, S., 
Amato, R. S., Bader, P., Browning, M. F., Haun, C. L., Duda, A. W., 3rd, Cheung, S. 
W. & Stankiewicz, P. (2010). Intragenic Rearrangements in Nrxn1 in Three Families 
www.intechopen.com
 
Autism – A Neurodevelopmental Journey from Genes to Behaviour 
 
48
with Autism Spectrum Disorder, Developmental Delay, and Speech Delay. Am J 
Med Genet B Neuropsychiatr Genet, Vol.153B, No.5, Jul, pp.983-993,1552-485X  
Wisniewski, K. E., Segan, S. M., Miezejeski, C. M., Sersen, E. A. & Rudelli, R. D. (1991). The 
Fra(X) Syndrome: Neurological, Electrophysiological, and Neuropathological 
Abnormalities. Am J Med Genet, Vol.38, No.2-3, Feb-Mar, pp.476-480,0148-7299     
Witt Engerstrom, I. (1992). Age-Related Occurrence of Signs and Symptoms in the Rett 
Syndrome. Brain Dev, Vol.14 Suppl, May, pp.S11-20,0387-7604     
Wittner, L., Magloczky, Z., Borhegyi, Z., Halasz, P., Toth, S., Eross, L., Szabo, Z. & Freund, T. 
F. (2001). Preservation of Perisomatic Inhibitory Input of Granule Cells in the 
Epileptic Human Dentate Gyrus. Neuroscience, Vol.108, No.4, pp.587-600,0306-4522     
Wonders, C. P. & Anderson, S. A. (2006). The Origin and Specification of Cortical 
Interneurons. Nat Rev Neurosci, Vol.7, No.9, Sep, pp.687-696,1471-003X     
Wong, V. (1993). Epilepsy in Children with Autistic Spectrum Disorder. J Child Neurol, Vol.8, 
No.4, Oct, pp.316-322,0883-0738     
Wu, S., Yue, W., Jia, M., Ruan, Y., Lu, T., Gong, X., Shuang, M., Liu, J., Yang, X. & Zhang, D. 
(2007). Association of the Neuropilin-2 (Nrp2) Gene Polymorphisms with Autism 
in Chinese Han Population. Am J Med Genet B Neuropsychiatr Genet, Vol.144B, No.4, 
Jun 5, pp.492-495,1552-4841     
Yang, M. S. & Gill, M. (2007). A Review of Gene Linkage, Association and Expression 
Studies in Autism and an Assessment of Convergent Evidence. Int J Dev Neurosci, 
Vol.25, No.2, Apr, pp.69-85,0736-5748     
Yip, J., Soghomonian, J. J. & Blatt, G. J. (2007). Decreased Gad67 Mrna Levels in Cerebellar 
Purkinje Cells in Autism: Pathophysiological Implications. Acta Neuropathol, 
Vol.113, No.5, May, pp.559-568,0001-6322     
Yip, J., Soghomonian, J. J. & Blatt, G. J. (2008). Increased Gad67 Mrna Expression in 
Cerebellar Interneurons in Autism: Implications for Purkinje Cell Dysfunction. J 
Neurosci Res, Vol.86, No.3, Feb 15, pp.525-530,1097-4547     
Zhang, C., Atasoy, D., Arac, D., Yang, X., Fucillo, M. V., Robison, A. J., Ko, J., Brunger, A. T. 
& Sudhof, T. C. (2010). Neurexins Physically and Functionally Interact with Gaba(a) 
Receptors. Neuron, Vol.66, No.3, May 13, pp.403-416,1097-4199     
Zhu, Z. Q., Armstrong, D. L., Hamilton, W. J. & Grossman, R. G. (1997). Disproportionate 
Loss of Ca4 Parvalbumin-Immunoreactive Interneurons in Patients with Ammon's 
Horn Sclerosis. J Neuropathol Exp Neurol, Vol.56, No.9, Sep, pp.988-998,0022-3069     
www.intechopen.com
Autism - A Neurodevelopmental Journey from Genes to Behaviour
Edited by Dr. Valsamma Eapen
ISBN 978-953-307-493-1
Hard cover, 484 pages
Publisher InTech
Published online 17, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book covers some of the key research developments in autism and brings together the current state of
evidence on the neurobiologic understanding of this intriguing disorder. The pathogenetic mechanisms are
explored by contributors from diverse perspectives including genetics, neuroimaging, neuroanatomy,
neurophysiology, neurochemistry, neuroimmunology, neuroendocrinology, functional organization of the brain
and clinical applications from the role of diet to vaccines. It is hoped that understanding these interconnected
neurobiological systems, the programming of which is genetically modulated during neurodevelopment and
mediated through a range of neuropeptides and interacting neurotransmitter systems, would no doubt assist in
developing interventions that accommodate the way the brains of individuals with autism function. In keeping
with the multimodal and diverse origins of the disorder, a wide range of topics is covered and these include
genetic underpinnings and environmental modulation leading to epigenetic changes in the aetiology; neural
substrates, potential biomarkers and endophenotypes that underlie clinical characteristics; as well as
neurochemical pathways and pathophysiological mechanisms that pave the way for therapeutic interventions.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Sacha Genovesi, Giovanni Provenzano, Mark Dunleavy, Paola Sgado ̀ and Yuri Bozzi (2011). GABAergic
Dysfunction in Autism and Epilepsy, Autism - A Neurodevelopmental Journey from Genes to Behaviour, Dr.
Valsamma Eapen (Ed.), ISBN: 978-953-307-493-1, InTech, Available from:
http://www.intechopen.com/books/autism-a-neurodevelopmental-journey-from-genes-to-behaviour/gabaergic-
dysfunction-in-autism-and-epilepsy
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
